Suppr超能文献

合并用药后健康成年人中维洛沙嗪缓释片(SPN-812)和哌醋甲酯的药代动力学。

Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Methylphenidate in Healthy Adults.

机构信息

Supernus Pharmaceuticals, Inc., 9715 Key West Avenue, Rockville, MD, 20850, USA.

Department of Psychiatry/Behavioral Science, University of South Carolina School of Medicine, Greenville, SC, USA.

出版信息

Clin Drug Investig. 2021 Feb;41(2):149-159. doi: 10.1007/s40261-020-00992-6. Epub 2020 Dec 23.

Abstract

BACKGROUND AND OBJECTIVES

Viloxazine extended-release (viloxazine ER, SPN-812) is a novel non-stimulant with activity at serotonin receptors and the norepinephrine transporter, which is under investigation as a potential treatment for attention-deficit/hyperactivity disorder. Given the potential for viloxazine ER to be coadministered with other pharmacotherapies, this trial investigated the pharmacokinetics and safety of combination viloxazine ER + methylphenidate versus viloxazine ER or methylphenidate alone.

METHODS

In this single-center, crossover, open-label trial, healthy adult participants received oral administration of 700 mg viloxazine ER alone, 36 mg methylphenidate alone, and combination viloxazine ER (700 mg) + methylphenidate (36 mg), with blood samples collected over 4 days post-administration. The active drug in viloxazine ER (viloxazine) and methylphenidate was measured using chromatographic tandem mass spectrometry. Safety assessments included adverse events (AEs), vital signs, echocardiograms, and clinical laboratory evaluations.

RESULTS

Of 36 healthy adults who were enrolled, 34 completed the trial. The geometric least squares mean ratios are reported as [combination/single drug (90% confidence intervals)]. For viloxazine ER, maximum measured plasma concentration (C) = 100.98% (96.21-105.99), area under the concentration-time curve from time zero to the last measurable time (AUC) = 98.62% (96.21-101.08), and area under the concentration-time curve from time zero to infinity (AUC) = 98.96% (96.55-101.44). For methylphenidate, C = 103.55% (97.42-110.07), AUC = 106.67% (101.01-112.64), and AUC = 106.61% (100.99-112.54). All reported AEs were mild in severity.

CONCLUSIONS

Coadministration of viloxazine ER and methylphenidate did not impact the pharmacokinetics of viloxazine or methylphenidate relative to administration of either drug alone. The combination appeared to be safe and well tolerated.

摘要

背景与目的

Viloxazine 缓释片(viloxazine ER,SPN-812)是一种新型非兴奋剂,对 5-羟色胺受体和去甲肾上腺素转运体具有活性,目前正在作为治疗注意缺陷多动障碍的潜在药物进行研究。鉴于 viloxazine ER 可能与其他药物联合使用,本试验研究了 viloxazine ER+哌甲酯与 viloxazine ER 或哌甲酯单独给药的药代动力学和安全性。

方法

在这项单中心、交叉、开放标签试验中,健康成年参与者口服给予 700mg 单独的 viloxazine ER、36mg 单独的哌甲酯以及组合 viloxazine ER(700mg)+哌甲酯(36mg),在给药后 4 天内采集血样。使用色谱串联质谱法测量 viloxazine ER 中的活性药物(viloxazine)和哌甲酯。安全性评估包括不良事件(AE)、生命体征、超声心动图和临床实验室评估。

结果

在 36 名入组的健康成年人中,有 34 名完成了试验。几何最小二乘均值比报告为[组合/单药(90%置信区间)]。对于 viloxazine ER,最大实测血浆浓度(C)=100.98%(96.21-105.99),从零时到最后可测量时间的浓度-时间曲线下面积(AUC)=98.62%(96.21-101.08),从零时到无穷大的浓度-时间曲线下面积(AUC)=98.96%(96.55-101.44)。对于哌甲酯,C=103.55%(97.42-110.07),AUC=106.67%(101.01-112.64),AUC=106.61%(100.99-112.54)。所有报告的不良事件均为轻度。

结论

viloxazine ER 与哌甲酯联合给药不会影响 viloxazine 或哌甲酯的药代动力学,与单独使用任何一种药物相比。联合用药似乎是安全且耐受良好的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06f9/7886742/4faba0610fc3/40261_2020_992_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验